Publications by authors named "Henegar C"

Background: Real-world data on treatment patterns and clinical outcomes for newer drugs, including integrase strand transfer inhibitors, among older people with human immunodeficiency virus (PWH) are limited.

Methods: This cohort study included PWH enrolled in the Veterans Aging Cohort Study (VACS) who were prescribed a standard 3-drug antiretroviral therapy (ART) regimen containing dolutegravir (DTG), bictegravir (BIC), cobicistat boosted elvitegravir (EVG), raltegravir (RAL), or darunavir/ritonavir (DRV) plus 2 nucleoside reverse transcriptase inhibitors between January 1, 2014, and March 31, 2020, and who were ≥50 years at regimen initiation. The association between regimen and virologic effectiveness or discontinuation was assessed using logistic regression models with inverse probability of treatment weights.

View Article and Find Full Text PDF

Background: Two-drug regimens (2DRs) have been introduced in recent years to potentially reduce antiretroviral therapy (ART) toxicities and drug-drug interactions while demonstrating comparable efficacy to three-drug regimens (3DRs) for people with HIV (PWH). The objective of this study was to compare the real-world effectiveness and durability of a single-tablet 2DR of dolutegravir/lamivudine (DTG/3TC) with that of commonly prescribed 3DRs in ART-experienced, virologically suppressed PWH during the first 24 months of DTG/3TC availability in the United States.

Methods: Virologically suppressed (viral load [VL] < 200 copies/mL) adult PWH initiating DTG/3TC 2DR, bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), or a DTG-based 3DR between 01MAY2019 and 31OCT2020 were identified in the OPERA cohort and followed through 30APR2021.

View Article and Find Full Text PDF
Article Synopsis
  • Fostemsavir is a new drug used alongside other treatments for adults with multidrug-resistant HIV-1, focusing on its real-world effects in the OPERA cohort.
  • The study analyzed immunological (CD4 T-cell counts) and virological (viral load) responses in participants starting fostemsavir, categorizing results based on their initial viral load and CD4 count.
  • Results showed that while most individuals with suppressed viral loads maintained their status, those with low CD4 counts had notable improvements in immune response with fostemsavir, despite limited virological success in those who were viraemic.
View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the effectiveness of the two-drug regimen (DTG/3TC) for HIV treatment, focusing on individuals transitioning from a three-drug regimen while maintaining a viral load under 50 copies/mL.
  • It includes 787 treatment-experienced participants followed for a median of 13.6 months, finding low rates of virologic failure and loss of viral control.
  • Results indicate that DTG/3TC is a viable and generally well-tolerated option for HIV treatment across different age, sex, and racial groups.
View Article and Find Full Text PDF

Coronary artery disease (CAD) remains the leading cause of mortality and morbidity worldwide. Recent advances in large-scale genome-wide association studies have highlighted the potential of genetic risk, captured as polygenic risk scores (PRS), in clinical prevention. However, the current clinical utility of PRS models is limited to identifying high-risk populations based on the top percentiles of genetic susceptibility.

View Article and Find Full Text PDF

After a decade of dolutegravir (DTG) use in various antiretroviral therapy combinations and in diverse populations globally, it is critical to identify HIV strains with reduced drug susceptibility and monitor emergent resistance in people living with HIV who experience virologic failure while on DTG-based regimens. We searched the PubMed, Embase, and Cochrane databases to identify studies that reported DTG resistance-associated mutations (RAMs) emerging under selection pressure. Our review showed that RAMs conferring resistance to DTG were rare in 2-drug and 3-drug regimens used in real-world cohorts, corroborating data from clinical trials.

View Article and Find Full Text PDF

Adipose tissue macrophages (ATMs) play an important role in obesity and inflammation, and they accumulate in adipose tissue (AT) with aging. Furthermore, increased ATM senescence has been shown in obesity-related AT remodeling and dysfunction. However, ATM senescence and its role are unclear in age-related AT dysfunction.

View Article and Find Full Text PDF
Article Synopsis
  • - The study compared clinical outcomes between heavily treatment-experienced (HTE) and non-HTE people living with HIV (PLWH), focusing on their ART regimens and resistance to treatments over a median follow-up of 28 months.
  • - Results indicated that HTE PLWH had lower chances of achieving undetectable viral loads and maintaining adequate CD4 cell counts compared to non-HTE PLWH, and they were also more likely to need changes in their treatment regimens.
  • - Both groups experienced non-AIDS defining morbidities, with a higher prevalence in HTE PLWH (45%) versus non-HTE (35%), though serious morbidities and deaths were relatively rare.
View Article and Find Full Text PDF

Interactions between diet and gut microbiota are critical regulators of energy metabolism. The effects of fibre intake have been deeply studied but little is known about the impact of proteins. Here, we investigated the effects of high protein supplementation (Investigational Product, IP) in a double blind, randomised placebo-controled intervention study (NCT01755104) where 107 participants received the IP or an isocaloric normoproteic comparator (CP) alongside a mild caloric restriction.

View Article and Find Full Text PDF

In the context of obesity, senescent cells accumulate in white adipose tissue (WAT). The cellular underpinnings of WAT senescence leading to insulin resistance are not fully elucidated. The objective of the current study was to evaluate the presence of WAT senescence early after initiation of high-fat diet (HFD, 1-10 weeks) in 5-month-old male C57BL/6J mice and the potential role of energy metabolism.

View Article and Find Full Text PDF

With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess the association between ART regimens and changes in body mass index (BMI) among ART-experienced, virologically suppressed PLWH. ART-experienced, virologically suppressed PLWH ≥18 years of age in the Observational Pharmacoepidemiology Research and Analysis (OPERA) cohort were included for analysis if prescribed a new regimen containing one of the following core agents: dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), raltegravir (RAL), rilpivirine (RPV), or boosted darunavir (bDRV), for the first time between August 1, 2013 and December 31, 2017.

View Article and Find Full Text PDF

One of the most iconic wild equids, the plains zebra occupies a broad region of sub-Saharan Africa and exhibits a wide range of phenotypic diversity in stripe patterns that have been used to classify multiple subspecies. After decades of relative stability, albeit with a loss of at least one recognized subspecies, the total population of plains zebras has undergone an approximate 25% decline since 2002. Individuals with abnormal stripe patterns have been recognized in recent years but the extent to which their appearance is related to demography and/or genetics is unclear.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined weight changes among people living with HIV starting different antiretroviral therapy (ART) regimens from 2012 to 2019.
  • Compared to the efavirenz/tenofovir disoproxil fumarate/emtricitabine regimen, newly initiated regimens like bictegravir/TAF/FTC and dolutegravir/TAF/FTC showed significantly higher weight gain in the first 6 months.
  • Over a longer follow-up, darunavir/TDF/FTC also led to increased weight gain compared to other regimens, indicating that different ART regimens can significantly affect weight outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • The study examines how common prediabetes and type 2 diabetes (T2DM) are among people living with HIV (PLHIV) and investigates the impact of different antiretroviral therapy (ART) regimens on the risk of developing T2DM.
  • By analyzing the health records of nearly 30,000 PLHIV, researchers found that the prevalence of prediabetes was around 8-11% and T2DM was 4-10%, with incidence rates varying for ART-naive and ART-experienced individuals.
  • The results indicated no significant differences in T2DM risk associated with ART regimens like dolutegravir compared to others (elvite
View Article and Find Full Text PDF

Introduction: Two-drug regimens (2-DR) have the potential to be a viable solution to the challenges of treatment complexity, cost, adverse effects and contraindications. We sought to describe the real-world use and effectiveness of 2-DR among persons living with HIV (PLHIV) in the United States.

Methods: We analysed data for 10,190 treatment-experienced patients from the OPERA® Observational Database initiating a new 2-DR or three-drug regimen (3-DR) between 1 January 2010 and 30 June 2016.

View Article and Find Full Text PDF

Background: Women face unique complexities in HIV treatment yet are underrepresented in antiretroviral therapy (ART) studies.

Objective: This analysis assessed the one-year durability of the first integrase strand transfer inhibitor (INSTI)-based regimens prescribed to women in a large cohort of patients living with HIV in care.

Methods: Women with HIV who initiated their first INSTI-containing regimen between 08/12/2013 and 11/30/2015 were identified in the OPERA cohort, a collaboration of 79 US outpatient clinics.

View Article and Find Full Text PDF

Background: Pretreatment and acquired drug resistance mutations (DRMs) can limit antiretroviral therapy effectiveness.

Methods: We review prevalence of DRMs with resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), focusing on lamivudine and rilpivirine, from 127 articles with >100,000 individuals with HIV-1 infection.

Results: Estimated global prevalence of pretreatment resistance to any NRTI was 4% and to any NNRTI was 6%.

View Article and Find Full Text PDF
Article Synopsis
  • - HLA-B*57:01 screening was introduced in 2008 to minimize the risk of hypersensitivity reactions in patients starting abacavir, with a study analyzing its uptake and effectiveness in the US.
  • - From 1999 to 2016, the percentage of patients screened for HLA-B*57:01 prior to starting abacavir rose significantly from 43% in 2009 to 84% in 2015, while hypersensitivity reactions dropped from 1.3% to 0.2% during the same timeframe.
  • - Despite the increased screening rates, many patients still underwent abacavir treatment without screening, indicating areas for improvement in preventing potential hypersensitivity reactions.
View Article and Find Full Text PDF

Background: Psychiatric outcomes are common among people living with HIV and may be associated with specific antiretroviral use. We evaluated the occurrence of psychiatric outcomes in patients taking dolutegravir (DTG)-containing regimens compared with five other core agents.

Methods: Patients in the OPERA database prescribed regimens based on DTG, efavirenz (EFV), raltegravir (RAL), darunavir (DRV), rilpivirine (RPV), or elvitegravir (EVG) for the first time between 1 January 2013 and 31 December 2015 were analyzed.

View Article and Find Full Text PDF

Introduction: Human leukocyte antigen (HLA)-B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and human immunodeficiency virus treatment guidelines in 2008. Company meta-analyses of trials pre-HLA-B*5701 screening reported HSR rates of 4-8%.

View Article and Find Full Text PDF

Background: Aging induces cardiac structural and functional changes linked to the increased deposition of extracellular matrix proteins, including OPN (osteopontin), conducing to progressive interstitial fibrosis. Although OPN is involved in various pathological conditions, its role in myocardial aging remains unknown.

Methods: OPN deficient mice (OPN-/-) with their wild-type (WT) littermates were evaluated at 2 and 14 months of age in terms of cardiac structure, function, histology and key molecular markers.

View Article and Find Full Text PDF

Background: Type 2 diabetes mellitus (T2DM) may alter cardiac structure and function, but obesity, hypertension (HTN), or aging can induce similar abnormalities.

Objectives: This study sought to link cardiac phenotypes in T2DM patients with clinical profiles and outcomes using cluster analysis.

Methods: Baseline echocardiography and a composite endpoint (cardiovascular mortality and hospitalization) were evaluated in 842 T2DM patients from 2 prospective cohorts.

View Article and Find Full Text PDF

Obesity-induced white adipose tissue (WAT) fibrosis is believed to accelerate WAT dysfunction. However, the cellular origin of WAT fibrosis remains unclear. Here, we show that adipocyte platelet-derived growth factor receptor-α-positive (PDGFRα) progenitors adopt a fibrogenic phenotype in obese mice prone to visceral WAT fibrosis.

View Article and Find Full Text PDF

Mammalian colour patterns are among the most recognizable characteristics found in nature and can have a profound impact on fitness. However, little is known about the mechanisms underlying the formation and subsequent evolution of these patterns. Here we show that, in the African striped mouse (Rhabdomys pumilio), periodic dorsal stripes result from underlying differences in melanocyte maturation, which give rise to spatial variation in hair colour.

View Article and Find Full Text PDF